Drug Discovery 2008
Posted: 2 August 2008 | EPR | No comments yet
Following the highly successful meeting in 2007, the European Laboratory Robotics Interest Group (ELRIG) and the Society of Biomolecular Sciences (SBS), are pleased to announce that their Drug Discovery: 2008 Meeting will be held at the Bournemouth International Centre, (BIC), UK, on 23 & 24 September 2008.
Following the highly successful meeting in 2007, the European Laboratory Robotics Interest Group (ELRIG) and the Society of Biomolecular Sciences (SBS), are pleased to announce that their Drug Discovery: 2008 Meeting will be held at the Bournemouth International Centre, (BIC), UK, on 23 & 24 September 2008.
Following the highly successful meeting in 2007, the European Laboratory Robotics Interest Group (ELRIG) and the Society of Biomolecular Sciences (SBS), are pleased to announce that their Drug Discovery: 2008 Meeting will be held at the Bournemouth International Centre, (BIC), UK, on 23 & 24 September 2008.
This conference will encompass six sessions in two days. Each will focus on a different area of Drug Discovery from selecting compounds for the corporate collection, liquid handling and detection technologies, plus advances in assay development and screening. Two sessions will address the biochemistry of two important different target classes: Enzymes and G-protein coupled receptors. Biopharmaceuticals will form the sixth session. As with the highly successful meeting in 2007, attendees will hear world class speakers discussing the challenges facing the drug discovery scientist. The scientific sessions will be complemented by plenary keynote presentations from two of the field’s foremost researchers, a poster session and a vendor exhibition with over eighty exhibitors.
Tuesday, 23 September
Drug Discovery for Enzyme Targets
Session Chairs: Andreas Sewing, Pfizer and Niall Martin, Kudos Pharma
- Strategies for Kinase inhibitor Discovery
Ulf Boemer, Bayer
- Inhibition of poly(ADR-ribose) polymerse – a case history
Nicola Curtin, CRUK
- The challenges of viral enzymes as drug discovery targets
Spencer Campbell, Arrow Therapeutics
- Shifting paradigms on enzyme- based high throughput Assays
J M Dominguez, GSK
- Streamlined analysis of kinetics screening data – As simple as possible, but not simpler
Stephan Heyse, Genedata
Compound Management Diversifying the Corporate Collection
Session Chairs: Stephen Garland, GSK and John Morin, Wyeth
- An Integrated Approach to Drug Discovery in the 21st Century; Working beyond our walls
Nunzio Sciammetta, Pfizer
- Maintaining a High Quality Compound Collection: The GSK Experience
Zoe Blaxill, GSK
- To Serve & Protect: Compound Management for Discovery Research
John Morin, Wyeth
- Libraries for Fragment Screening
Ijen Chen, Vernalis
- Building a high quality screening library from commercial sources
Justin Bryans, MRCT
- Application of Chemogenomics to Compound Design
Steve Garland, GSK
The Hard Cell: Current issues in Drug Discovery and Screening
Session Chairs: Richard Eglen, Perkin Elmer and Martin Coldwell, AstraZeneca
- Experiences of the Application of Label-Free Technologies for compound profiling in cell- base assays
Kathy Dodgson, AstraZeneca
- Cell Based Screening for GPCR Ligands; Strategies, Successes and Future Challenges
Steve Rees, GSK
- Title to be confirmed
Stefan Precti, Bayer
- Screening Biologics in Cell Based Assays
Paula Harrison, Medlmmure
- Ion channel targets and HTS: a comprehensive platform of luminescent and fluorescent cellular-based assays
Viviana Agus, Axxam
- Development of KinobeadsTM assays for lead optimisation
Dan Leggate, Cellzome
Wednesday, 24 September
Liquid Handling and Detection Technologies
Session Chairs: Graeme Daniels, Tecan, Eric Tang, AZ and John Comley, HTStec
- FDSS7000, a novel 1536 well multi-readout cellular assay platform for kinetic assays
Rochdi Bouhelal, Novartis
- HTS operations: How to choose the right components?
Sabrinna Corazza, Axxam
- Leveraging Hybrid Microplate Detection to Optimize Enabling Assay Technologies for Cell Signaling and Membrane Targets
Kevin Lowitz, Invitrogen
- Title to be confirmed
Eric Tang, AstraZeneca
- Title to be confirmed
Florian Hollfelder, Cambs Uni
Biopharmaceutical Drug Discovery
Session Chairs: Sandra Turconi, Ablynx and Richard Pither, UCB
- The Application of SPR and Kinetic Screening to Antibody selection
Robert Karlsson, GE Healthcare
- Antibodies as Therapeutics and Tools in Drug Discovery
Alastair Lawson, UCB
- Overcoming Adverse Immunogenicity Against Therapeutic Antibodies
Matthew Baker, Antitope
- High density screening of domain antibodies
Rosemary Sasse, GSK
- Monoclonal Antibody Generation with LIMS and Automation integration
Trevor Wattam, GSK
- Nanoclone®: A novel high-throughput technology for isolating heavy chain antibody variable domains from single B-cells
Joost Kolkman, Ablynx
Drug Discovery for GPCR targets
Session Chairs: Stephen Hill, Nottingham University and Fiona Marshall, Heptares
- New Tools for Studying GPCR Targets
Annette Gilchrist, Caden Bio
- Engineering stabilised GPCRs in agonist and antagonist conformations
Fiona Marshall, Heptares Therapeutic
- Structure based design of adenosine receptor antagonists
Stefano Moro, Uni of Padova
- Structure of the Beta Adrenergic Receptors: Progress in obtaining recombinant G protein Coupled Receptor Structure
Gebhard Schertler, Cambridge
- Label-free technology fulfilling the potential for GPCR drug discovery
Martyn Wood, GSK
- Development of Allosteric Modulators of GPCSs as a Novel Approach for the Treatment of CNS Disorders
Carrie Jones, Vanderbilt Uni
